Global Alzheimer's Disease Drug Market Growth 2023-2029

Global Alzheimer's Disease Drug Market Growth 2023-2029

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
LPI (LP Information)' newest research report, the “Alzheimer's Disease Drug Industry Forecast” looks at past sales and reviews total world Alzheimer's Disease Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Alzheimer's Disease Drug sales for 2023 through 2029. With Alzheimer's Disease Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alzheimer's Disease Drug industry.
This Insight Report provides a comprehensive analysis of the global Alzheimer's Disease Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alzheimer's Disease Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Alzheimer's Disease Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alzheimer's Disease Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alzheimer's Disease Drug.
The global Alzheimer's Disease Drug market size is projected to grow from US$ 3539.3 million in 2022 to US$ 3943.3 million in 2029; it is expected to grow at a CAGR of 3943.3 from 2023 to 2029.
The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer's Disease Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Donepezil
Memantine
Rivastigmine
Others
Segmentation by application
Early to Moderate Stages
Moderate to Severe Stages
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Key Questions Addressed in this Report
What is the 10-year outlook for the global Alzheimer's Disease Drug market?
What factors are driving Alzheimer's Disease Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Alzheimer's Disease Drug market opportunities vary by end market size?
How does Alzheimer's Disease Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.